Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
PEPTICHIP: Streamlined identification of tumour neoantigens for personalised anti-cancer immunotherapy (PeptiCHIP)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Finland
Call: ERC Proof of Concept Grant (ERC-2019-PoC, 2019)
Start date: 2019-10-01
End date: 2021-09-30
Duration (months): 24.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Immunotherapeutic strategies have emerged as powerful tools to treat many types of cancers. However, the majority of patients still fails to respond to immunotherapies as targetable tumour characteristics vary from patient to patient. Thus, a greater degree of personalisation is required to fine-tune immunotherapies to the specific vulnerabilities of each patient’s tumour. While therapies that target tumour-specific antigens (neoantigens) invoke a strong and specific anti-tumour immune response, we are currently unable to accurately identify patient-specific neoantigens. Current neoantigen identification and purification methods either require impractically large quantities of tumour material or are laborious, expensive, time-consuming (weeks or months) and inaccurate. As part of ERC project PEPTICRAD (2016-2021), Prof. Vincenzo Cerullo at the University of Helsinki has developed a novel microfluidic chip-based device (PeptiCHIP) which condenses the neoantigen purification steps into a single chip capable of accurately analysing minute quantities of human tumour tissue. PeptiCHIP permits cost-effective, rapid, sample-conserving, user-friendly, accurate and standardised tumour neoantigen identification, thereby unleashing the full potential of personalised anti-tumour immunotherapies. In this ERC PoC project, a team of technological and commercial experts will ascertain the technical and commercial viability of the innovative PeptiCHIP device. We will prepare the first steps toward the start-up of a spin-off by defining the most optimal business strategy and model. Furthermore, we will explore the technical potential of the PeptiCHIP and solidify our IP-position. We will develop a solid business strategy based on the technological aspects, the market needs and trends. Finally, during this project we will gain technical and commercial proof-of-concept, providing the necessary information for potential commercialisation routes.

Keywords: immunotherapy,oncoimmunology,tumor antigens,neoantigens,cancer immunotherapy,virotherapy,oncolytic virus
Sea Change (SeaChange)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Action type: Coordination and support actions
Countries involved: Spain,Estonia,Ireland,Spain,Argentina,Ireland,Belgium,Belgium,Belgium,Sweden,Greece,Bulgaria,France,France,France,Czechia,Portugal,Denmark,United Kingdom,United Kingdom,Portugal,United Kingdom
Call: Ocean literacy – Engaging with society – Social Innovation (H2020-BG-2014-1, 2014)
Start date: 2015-03-01
End date: 2018-02-28
Duration (months): 36.0
Total project cost (EUR): 3494876.0
EU funding (EUR): 3494876.0
Participants: 24
Project status: CLOSED

The overarching goals of the Sea Change project are to bring about a fundamental “Sea Change” in the way European citizens view their relationship with the sea, by empowering them – as ‘Ocean Literate’ citizens - to take direct and sustainable action towards healthy seas and ocean, healthy communities and ultimately - a healthy planet. Key objectives of Sea Change are to: • Compile an in-depth review of the links between Seas and Ocean and Human health based on latest research knowledge outputs • Build upon the latest social research on citizen and stakeholder attitudes, perceptions and values to help design and implement successful mobilisation activities focused on education, community, governance actors and directly targeted at citizens. marine education • Build upon significant work to date, adopting best practice and embedding Ocean Literacy across established strategic initiatives and networks in order to help maximise impact and ensure sustainability • Ensure that efforts to sustain an Ocean Literate society in Europe continue beyond the life of Sea Change through codes of good practice, public campaigns and other ongoing community activities. • Ensure that all activities of Sea Change are carefully monitored and evaluated to ensure maximum sustainability, effectiveness and efficiency • Ensure Knowledge exchange with transatlantic partners to bring about a global approach to protecting the planet’s shared seas and ocean. The objectives will be achieved by a closely interlinked programme. Sea Change includes a mobilisation phase engaging with citizens, formal education and policy actors. Crucially the legacy of Sea Change, including continuing knowledge sharing with North America, are embedded within the project.

Keywords: seas and ocean health,behavioural change,engagement,transatlantic,citizens,environment,mutual learning,impact,marine,challenges,knowledge sharing
Golden Mycological Triangle – joining forces to exploit mycological biodiversity for novel anti-infectives and other beneficial metabolites (GoMyTri)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Research and innovation staff exchange
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Thailand,Netherlands
Call: Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) (H2020-MSCA-RISE-2014, 2014)
Start date: 2015-01-01
End date: 2018-12-31
Duration (months): 48.0
Total project cost (EUR): 333000.0
EU funding (EUR): 333000.0
Participants: 3
Project status: CLOSED

The proposed project aims at the intensification of cooperations between research infrastructure organisations in German, the Netherlands and Thailand that are recognised internationally as strongholds in mycological, biotechnological and microbiological research. The cooperation is intended to explore the mycological and microbiological biodiversity of Europe and Southeast Asia, in particular with regard to the search for the badly needed new antibiotics and other biologically active substances. The working plan includes activities such as the systematic exploration of fungal biodiversity by using modern molecular phylogenetic and chemotaxonomic techniques, as well as genome sequencing, in conjunction with classical microbiology. The focus of the research will be set on endophytes (in particular, Xylariaceae and Botryosphaeriaceae), invertebrate-associated ascomycetes (Cordycipitaceae), and marine fungi and fungal-like organisms, respectively. In addition, some basidiomycete cultures will also be studied. Between the participating partners already exist very good personal contacts and smaller research collaborations, which will be intensified in the context of the proposed project. Several staff exchanges and workshops are planned, which should allow the partners to further increase and optimise their interactions and to attain interdisciplinary skills. In the medium term the project is aimed at attaining an internationally visible strategic cooperation, including other departments of the institutions involved.

Keywords: fungi,mycology,bioprospecting,biotechnology,natural product discovery,antibiotic,biocontrol,endophyte
Market Release of a Portable Device for COVID-19 at the Point-of-Care; a Global Diagnostics Approach (IRIS-COV)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Action type: Innovation actions
Countries involved: South Africa,Belgium,Switzerland,Greece,France,United Kingdom
Call: Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL) (H2020-SC1-PHE-CORONAVIRUS-2020-2-CNECT, 2020)
Start date: 2020-11-01
End date: 2022-04-30
Duration (months): 18.0
Total project cost (EUR): 3069157.5
EU funding (EUR): 2384878.13
Participants: 8
Project status: CLOSED

The current pandemic of the coronavirus, reported first on 31st December 2019 in China, has produced a global alert of unprecedented nature. From the beginning, immediate actions have been put in place by all relevant stakeholders, i.e., local health departments, governments, pharmaceutical companies, global organisations etc., to address the problem as quickly as possible and control the spread of the disease. Large scale testing of symptomatic and asymptomatic patients/citizens has been one of the most effective measures taken by several countries, combined with isolation and tracking. Today, after six months from the outbreak, the deaths continue to rise with over 200 affected countries. Fear of a new wave of the pandemic together with the ongoing cases worldwide make the need for developing rapid and accurate diagnostic tools for COVID-19 a global priority, as declared by the WHO. The current consortium aims to join forces in the battle against the coronavirus by producing mature and robust solutions with immediate impact. The proposal is built around the implementation of an existing and patented device and methodology based on isothermal LAMP amplification and real time quantitative colorimetric detection. This mature methodology, currently of a technology readiness level of 7, has already been proven to be able to detect SARS-CoV-2 in patients’ samples with 97.4% sensitivity and 100% specificity. The main objectives of this proposal are thus the immediate deployment of the device following clinical validation and fast track certification. Arrangements for the large-scale production of the device and reagents will take place in parallel, followed by the provision of a full medical certification for COVID-19 and flu detection directly in crude samples and at the point-of-care. Global uptake of the two certified products together with global sharing of the project results are important deliverables of the proposal for the current and future epidemics.

Keywords: molecular diagnostics,lamp,point of care,portable device,3d printing
Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine (EbolaVac)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Action type: Research and Innovation actions
Countries involved: Germany,Switzerland,Belgium,United Kingdom
Call: Health (H2020-Adhoc-2014-20, 2014)
Start date: 2014-10-07
End date: 2018-04-06
Duration (months): 42.0
Total project cost (EUR): 22055090.9
EU funding (EUR): 15153216.0
Participants: 4
Project status: CLOSED

The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22 March in Guinea. As of 30 September 2014, the World Health Organization (WHO) reports the total number of cases in the current outbreak of Ebola virus disease (EVD) in West Africa at 7470, with 3431 deaths. The US Centers for Disease Control and Prevention states that the number of cases is currently doubling every 20 days and estimates the true number of cases at 2.5 times higher than that reported. Countries that have been affected are Guinea, Liberia, Nigeria, Senegal and Sierra Leone. Ten percent of fatalities have occurred among front line health care workers attempting to contain the epidemic. On 7 August 2014, the WHO requested that GSK “fully engage in WHO-coordinated efforts to test, license and make available safe and effective Ebola interventions” to assist in the control of the outbreak. Taking into account the early stage of development, EbolaVac seeks to accelerate the clinical development of the GSK chimpanzee adenovirus type 3 Ebolavirus Zaire (ChAd3-EBO Z) vaccine candidate to make the vaccine available to frontline health care workers at risk and to be used in the containment of EBOV outbreaks. The project specifically aims to: (i) complete Phase 1 development of the ChAd3-EBO Z vaccine by supporting a clinical study conducted in Lausanne, Switzerland (WP2); (ii) evaluate the ChAd3-EBO Z vaccine in Phase 2 testing on adults and children at established clinical study centers in West Africa outside the current most heavily affected countries of Guinea, Sierra Leone, and Liberia (WP3); (iii) investigate immunological effects of vaccination and the effect of booster vaccination (WP4) and (iv) centrally manage and analyse clinical study data (WP5). Besides using an innovative vaccine technology, much of the innovation of this program will reside in its capacity to implement vaccine evaluation under significant time pressure and complex logistical challenges while maintaining appropriate quality standards.

Keywords: ebola,emergency procedure,outbreak,vaccine
OCTOPUS: Oncological Concurrent Tomographic Optoacoustics, Pet and UltraSonography. (OCTOPUS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-06-01
End date: 2024-05-31
Duration (months): 24.0
Total project cost (EUR): 160932.48
EU funding (EUR): 160932.48
Participants: 1
Project status: CLOSED

Cancer is the second leading cause of death globally. Noninvasive imaging of tumor hallmarks helps to combat cancer more efficiently. However, cancer is a complex disease and modern imaging of cancer should evolve to help exploring the interaction between different cancer hallmarks and to predict the evolution of some of them in relation to others. Besides, these new techniques should provide answers to the present unmet need for determining, precisely, how, which and when targeted therapeutic agents can be used for optimized efficacy. In this project we will build a new hybrid cancer imaging device: OCTOPUS (Oncological Concurrent Tomographic Optoacoustics, PET and UltraSonography), that will pioneer the intersection of molecular, vascular and tissue oxygenation information, three major hallmarks of cancer. OCTOPUS is a timely action to study tumor dynamics with a hybrid hallmark perspective in a longitudinal, simultaneous, quantitative, fully co-registered and in vivo manner. To reach this goal, I will develop cutting-edges technologies regarding multispectral tomographic optoacoustic using an arrangement of 3D ultrasound arrays, combined with actual 3D sequences of Ultrafast Ultrasound and a custom-made PET system for data acquisition and reconstruction. A deep learning framework will be created for advanced multiparametric analysis of OCTOPUS derived data to facilitate the interpretation of intra-tumoral processes in order to improve high-precision image-guided treatment and ultimately to guide in the design of targeted therapies.

Keywords: hybrid imaging,imaging for oncology,ultrafast ultrasound,optoacoustics
Fibring of manifolds and groups (FIBRING)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Mathematics
Panel description: All areas of mathematics, pure and applied, plus mathematical foundations of computer science, mathematical physics and statistics
Countries involved: Germany,United Kingdom
Call: ERC Starting Grant (ERC-2019-STG, 2019)
Start date: 2020-07-01
End date: 2025-12-31
Duration (months): 66.0
Total project cost (EUR): 1498660.0
EU funding (EUR): 1498660.0
Participants: 2
Project status: SIGNED

The study of manifolds that fibre over the circle has a long and exciting history at the core of modern manifold topology, starting with Farrell's work on the problem in high ('surgery') dimensions, and running through the celebrated work of Stallings and Thurston in dimension 3, to Agol's 2013 solution of Thurston's virtual fibring conjecture. Parallel developments in group theory have placed the study of Bieri-Neumann-Strebel (BNS) invariants, which emerged in the 1980s, at the heart of the subject; these invariants describe when a group fibres, i.e. admits a map onto Z with finitely generated kernel. In the research outlined here a powerful new set of algebraic invariants - agrarian polytopes - will be used to establish a new frontier in the theory of fibring. The main goal is to achieve a complete description of all possible fibrings over the circle for aspherical manifolds in surgery dimensions. An agrarian polytope is a subset of the vector space H_1(X;R), where X is a group or a manifold. It is defined in the novel framework of agrarian invariants that I am developing, a theory that has already borne remarkable fruit. The theory provides algebraic counterparts to the (analytic) L2-invariants that have proved so powerful in geometric topology, group theory and global analysis over the last four decades. The primary focus of the research proposed here lies in establishing new deep connections between the algebra of group rings and their completions, and global properties of aspherical manifolds and groups. Three further goals of the proposal are: to develop the theory of agrarian invariants in positive characteristic; to show that agrarian invariants are profinitely rigid; to apply the new technology to the study of dynamical zeta functions. Each of these goals promises a breakthrough in its respective domain.

Keywords: fibring over the circle,bns invariants
Software defined networking architecture augmented with Artificial Intelligence to improve aeronautical communications performance, security and efficiency (SINAPSE)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Single European Sky Air Traffic Management Research
Action type: Research and Innovation actions
Partnership: SESAR (Art-187)
Countries involved: Austria,Spain,France,United Kingdom
Call: CNS for ATM (H2020-SESAR-2019-2, 2019)
Start date: 2020-05-01
End date: 2022-10-31
Duration (months): 30.0
Total project cost (EUR): 853300.0
EU funding (EUR): 853300.0
Participants: 4
Project status: CLOSED

The SINAPSE project aims at proposing an intelligent and secured aeronautical datalink communications network architecture design based on the Software Defined Networking (SDN) architecture model augmented with Artificial Intelligence (AI) to predict and prevent safety services outages, to optimize available network resources and to implement cybersecurity functions protecting the network against digital attacks

Keywords: datalink,artificial intelligence,machine learning,intelligent network,performance,capacity,resource optimization,cyber security
ADAPTABLE, COMPACT AND MAINTENANCE-FREE COOLING SYSTEMS FOR ONBOARD EQUIPMENT (COOLSOE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-12-01
End date: 2020-05-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

CEDRION, a company incubated in the European Space Agency Business Incubation Centre (ESA-BIC) program, provides refrigerating solutions to the new demands in the electronics industry. More specifically, CEDRION -which has an international patent requested since April 2019 on its technology- designs and produces refrigeration devices for on-board electronics, based on the Corona Discharge Effect. These devices, which are 10 times more efficient than present cooling technologies (heatsink, fan-assisted heatsink and thermoelectric) and do not have any moving parts, can extend the useful life of high-power on-board electronics by 30%, allowing on-board electronic equipment to have a better performance and reduce its maintenance costs. In fact, currently, one of the main technological challenges is to increase the efficiency of cooling systems for high-power electronic equipment. These demands are even more urgent on aeronautical sector, where it is necessary to provide innovative technological solutions on a continuous basis to meet the high market demands. To accomplish this objective, CEDRION has already validated COOLSOE devices with companies of the drone sector as DroneXServices. Furthermore, it has commercial agreements with aerospace mechatronics companies as SUMA Aerospace and AXTER AEROSPACE to test and certificate the devices for aeronautical market. Finally, the company has caught the attention of Hoovering Solutions, AeroTools, DIP solutions or Airbus, which have shown interest in CEDRION´s technology for their systems (see Section 4-5).

Keywords: refrigeration,cooling,device,more electric aircraft,corona discharge,cold atmospheric plasma
A revolutionary shape memory alloy-based disposable device for bladder cancer removal (U-TURBT)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: United Kingdom
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2019-02-01
End date: 2019-05-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Bladder cancer represents the 9th most common malignancy worldwide and the 4th most common in men. Globally approximately 2.5M people suffer from it, with 420,000 newly diagnosed cases each year. In Europe, a total of 118,000 new cases and 52,000 deaths are estimated annually. With population growth and ageing, the absolute incidence of bladder cancer might be further escalating. Despite the increasing incidences, the current treatments remain ineffective. The gold standard Trans-Urethral Resection of Bladder Tumour (TURBT) has up to 61% risk of tumour recurrence due to incomplete removal or tumour cell implantation during the procedure. CML introduces U-TURBT, an innovative disposable device for the treatment of bladder cancer. By covering and sealing the portion of bladder affected by the tumour, it avoids tumour cell spillage and dissemination. By minimising the risk of recurrence, U-TURBT improves patients’ health and quality of life, and cuts down the expenses of the healthcare providers relative to additional treatments. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, CML will upgrade the device to permit en bloc bladder tumour resection and extrication. Large scale clinical trial will then be initiated for obtaining CE mark as a medical device

Keywords: bladder cancer,medical device,resectoscopes,urethral resection of bladder tumour